Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review)
- PMID: 21494315
- PMCID: PMC3008561
- DOI: 10.3892/etm_00000037
Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review)
Abstract
The purpose of this article was to review the current strategies of targeted therapy to integrins and define the best course of future research in ovarian cancer targeting. Cell surface integrin targeting has been used as a strategy for targeted therapy of several diseases with some success. The combination of virotherapy and integrin-targeting shows promise as a method for targeting ovarian cancer. More specifically, targeting of ovarian cancer with integrin-directed adenoviruses may lead to therapy with fewer toxicities and side effects. This article offers a review of the benefits of integrin-specific targeted therapy for several diseases and proposes a unique anti-ovarian cancer strategy involving the combination of the above with virotherapy as a potential anti-ovarian cancer treatment.
Similar articles
-
Targeting Integrins in Cancer Nanomedicine: Applications in Cancer Diagnosis and Therapy.Cancers (Basel). 2019 Nov 13;11(11):1783. doi: 10.3390/cancers11111783. Cancers (Basel). 2019. PMID: 31766201 Free PMC article. Review.
-
Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review.Cancers (Basel). 2017 Jul 8;9(7):83. doi: 10.3390/cancers9070083. Cancers (Basel). 2017. PMID: 28698469 Free PMC article. Review.
-
Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).Gynecol Oncol. 2007 Apr;105(1):113-21. doi: 10.1016/j.ygyno.2006.10.057. Epub 2006 Dec 14. Gynecol Oncol. 2007. PMID: 17173958
-
MicroRNAs Can Influence Ovarian Cancer Progression by Dysregulating Integrin Activity.Cancers (Basel). 2023 Sep 8;15(18):4449. doi: 10.3390/cancers15184449. Cancers (Basel). 2023. PMID: 37760437 Free PMC article. Review.
-
Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.Oncotarget. 2016 May 10;7(19):27926-37. doi: 10.18632/oncotarget.8545. Oncotarget. 2016. PMID: 27056886 Free PMC article.
Cited by
-
The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer.Biomolecules. 2023 Jan 12;13(1):159. doi: 10.3390/biom13010159. Biomolecules. 2023. PMID: 36671544 Free PMC article. Review.
-
Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.Drug Des Devel Ther. 2019 Sep 17;13:3281-3290. doi: 10.2147/DDDT.S211168. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31571830 Free PMC article.
-
Prostaglandins in cancer cell adhesion, migration, and invasion.Int J Cell Biol. 2012;2012:723419. doi: 10.1155/2012/723419. Epub 2012 Feb 29. Int J Cell Biol. 2012. PMID: 22505934 Free PMC article.
-
Angiogenesis in cancer: Anti-VEGF escape mechanisms.Transl Lung Cancer Res. 2012 Mar;1(1):14-25. doi: 10.3978/j.issn.2218-6751.2011.11.02. Transl Lung Cancer Res. 2012. PMID: 25806151 Free PMC article. Review.
-
Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer model.J Mol Biochem. 2012 Feb 15;1(1):26-39. J Mol Biochem. 2012. PMID: 23998042 Free PMC article.
References
-
- Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12:697–715. - PubMed
-
- Hynes RO. Cell adhesion: old and new questions. Trends Cell Biol. 1999;9:M33–M37. - PubMed
-
- Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389–395. - PubMed
-
- Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 1995;270:1500–1502. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources